Synovus Financial Corp Trims Stake in Omnicell, Inc. (OMCL)

Synovus Financial Corp cut its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 12.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,271 shares of the company’s stock after selling 2,379 shares during the period. Synovus Financial Corp’s holdings in Omnicell were worth $1,166,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Trillium Asset Management LLC boosted its stake in shares of Omnicell by 2.0% during the 2nd quarter. Trillium Asset Management LLC now owns 46,249 shares of the company’s stock worth $2,426,000 after purchasing an additional 923 shares during the period. Wrapmanager Inc. boosted its stake in shares of Omnicell by 18.7% during the 2nd quarter. Wrapmanager Inc. now owns 7,359 shares of the company’s stock worth $386,000 after purchasing an additional 1,160 shares during the period. Janney Capital Management LLC boosted its stake in shares of Omnicell by 11.3% during the 2nd quarter. Janney Capital Management LLC now owns 11,780 shares of the company’s stock worth $618,000 after purchasing an additional 1,200 shares during the period. Paloma Partners Management Co boosted its stake in shares of Omnicell by 25.6% during the 2nd quarter. Paloma Partners Management Co now owns 5,989 shares of the company’s stock worth $314,000 after purchasing an additional 1,222 shares during the period. Finally, Kopp Investment Advisors LLC boosted its stake in shares of Omnicell by 2.6% during the 2nd quarter. Kopp Investment Advisors LLC now owns 69,077 shares of the company’s stock worth $3,623,000 after purchasing an additional 1,757 shares during the period. 98.80% of the stock is owned by hedge funds and other institutional investors.

Shares of OMCL opened at $69.70 on Wednesday. Omnicell, Inc. has a fifty-two week low of $39.75 and a fifty-two week high of $73.00. The company has a market capitalization of $2.72 billion, a PE ratio of 387.22, a price-to-earnings-growth ratio of 4.14 and a beta of 0.98. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32.

OMCL has been the subject of a number of recent analyst reports. TheStreet raised shares of Omnicell from a “c+” rating to a “b” rating in a research note on Friday, July 27th. Benchmark boosted their price objective on shares of Omnicell from $66.00 to $79.00 and gave the company a “buy” rating in a research report on Friday, October 5th. BidaskClub cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Cantor Fitzgerald reissued a “buy” rating and issued a $63.00 price objective on shares of Omnicell in a research report on Thursday, July 26th. Finally, Craig Hallum raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Friday, July 27th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Omnicell has an average rating of “Buy” and a consensus price target of $69.86.

In other news, EVP Dan S. Johnston sold 6,250 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $63.47, for a total value of $396,687.50. Following the completion of the sale, the executive vice president now owns 35,996 shares of the company’s stock, valued at approximately $2,284,666.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James T. Judson sold 2,443 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $70.67, for a total transaction of $172,646.81. Following the completion of the sale, the director now directly owns 24,952 shares of the company’s stock, valued at approximately $1,763,357.84. The disclosure for this sale can be found here. Insiders sold a total of 24,277 shares of company stock valued at $1,654,248 in the last ninety days. Corporate insiders own 3.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Synovus Financial Corp Trims Stake in Omnicell, Inc. (OMCL)” was first posted by WKRB News and is the property of of WKRB News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/07/synovus-financial-corp-trims-stake-in-omnicell-inc-omcl.html.

Omnicell Profile

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Featured Article: Day Trading

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply